Synthetic oligonucleotides are promising therapeutic agents for the treatment of many diseases, including viral infections and cancer. Several classes of nucleic acids, such as antisense oligonucleotides, small interfering RNAs (siRNAs), and aptamers, are being investigated for therapeutic applications. However, impurities arising from incomplete capping of coupling reactions, product-related impurities, impurities in the starting materials, and impurities from post-synthesis processing must be monitored, identified, and removed.
A key challenge in the development and manufacture of oligonucleotide therapeutics is the need for analytical methods to separate and identify impurities. Agilent AdvanceBio Oligonucleotide columns are designed for ion-pair reversed-phase separation of the trityl-off, deprotected oligos using either TEAA or TEA-HFIP.